Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,890 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Cancer Patients Clear all
Completed Phase 1 Interventional

Tributyrin in Treating Patients With Refractory Prostate Cancer or Other Solid Tumors

NCT00002677
View directory record Official record
Conditions
Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
chemotherapy, tributyrin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2003
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 29, 2026, 5:49 PM EDT
Completed Phase 1 Interventional

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

NCT00031681
View directory record Official record
Conditions
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Estrogen Receptor-negative Breast Cancer, Extensive Stage Small Cell Lung Cancer, Gastrointestinal Stromal Tumor, HER2-negative Breast Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Primary Liver Cancer, Recurrent Anal Cancer, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Borderline Ovarian Surface Epithelial-stromal Tumor, Recurrent Breast Cancer, Recurrent Cervical Cancer, Recurrent Colon Cancer, Recurrent Endometrial Carcinoma, Recurrent Esophageal Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Prostate Cancer, Recurrent Rectal Cancer, Recurrent Salivary Gland Cancer, Recurrent Small Cell Lung Cancer, Recurrent Small Intestine Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Small Intestine Adenocarcinoma, Small Intestine Leiomyosarcoma, Small Intestine Lymphoma, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Anal Cancer, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Borderline Ovarian Surface Epithelial-stromal Tumor, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Endometrial Carcinoma, Stage IV Esophageal Cancer, Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IV Gastric Cancer, Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Prostate Cancer, Stage IV Rectal Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Triple-negative Breast Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions
7-hydroxystaurosporine, irinotecan hydrochloride, diagnostic laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 29, 2026, 5:49 PM EDT
Completed Not applicable Interventional

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

NCT02346253
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions
Internal Radiation Therapy, Bicalutamide, Leuprolide Acetate, Goserelin Acetate, Triptorelin Pamoate, Degarelix, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Radiation · Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
Male only
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 29, 2026, 5:49 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence

NCT02918357
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ga-68 labeled PSMA-11 PET
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Oct 29, 2026, 5:49 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer

NCT00003400
View directory record Official record
Conditions
Prostate Cancer
Interventions
filgrastim, carmustine, cisplatin, melphalan, vinorelbine tartrate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2019 · Synced Oct 29, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer

NCT00006101
View directory record Official record
Conditions
Prostate Cancer
Interventions
eflornithine, Placebo
Drug
Lead sponsor
Thomas E. Ahlering
Other
Eligibility
35 Years to 70 Years · Male only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2012
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 29, 2026, 5:49 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

NCT03367702
View directory record Official record
Conditions
Stage II Prostate Adenocarcinoma AJCC v7
Interventions
Intensity-Modulated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
276
States / cities
Mobile, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 230 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 29, 2026, 5:49 PM EDT
Terminated Phase 2 Interventional Results available

Licorice Root Extract and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00176631
View directory record Official record
Conditions
Prostate Cancer
Interventions
licorice root extract, docetaxel
Dietary Supplement · Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 29, 2026, 5:49 PM EDT
Not listed Phase 3 Interventional Results available

Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer

NCT00567580
View directory record Official record
Conditions
Prostate Cancer
Interventions
PBRT, PLNRT, AA, LHRH agonist
Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
1,792 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
444
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 316 more
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 29, 2026, 5:49 PM EDT
Withdrawn Not applicable Interventional

Pelvic Health and Physical Therapy to Improve Lives of Prostate Cancer Patients Undergoing Prostatectomy

NCT04027270
View directory record Official record
Conditions
Prostate Cancer
Interventions
Physical Therapy
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 29, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

GM-CSF in Treating Patients With Relapsed Prostate Cancer

NCT00908141
View directory record Official record
Conditions
Prostate Cancer
Interventions
sargramostim
Biological
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 29, 2026, 5:49 PM EDT
Available No phase listed Expanded access

Single Patient Compassionate Use of X-PACT in Salvage Treatment of Prostate Cancer

NCT06836648
View directory record Official record
Conditions
Prostate Cancer
Interventions
X-PACT
Combination Product
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 29, 2026, 5:49 PM EDT
Completed Phase 2 Interventional

Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate Cancer

NCT00059943
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Prostate Cancer
Interventions
docetaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 29, 2026, 5:49 PM EDT
Recruiting Phase 1Phase 2 Interventional

Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer

NCT07182279
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma)
Interventions
Brachytherapy
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
40 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 29, 2026, 5:49 PM EDT
Terminated Phase 2 Interventional Results available

Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer

NCT02168062
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Behavioral Dietary Intervention, Counseling, Educational Intervention, Exercise Intervention, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide Acetate, Quality-of-Life Assessment, Triptorelin Pamoate
Behavioral · Other · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Oct 29, 2026, 5:49 PM EDT
Completed No phase listed Observational

Magnetic Resonance Imaging of Lymph Nodes Using Ferumoxytol in Patients With Primary Prostate or Breast Cancer

NCT00087347
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer
Interventions
ferumoxytol, magnetic resonance imaging
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 29, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery

NCT01433913
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions
metformin hydrochloride, placebo, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Tucson, Arizona • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Oct 29, 2026, 5:49 PM EDT
Completed Phase 1 Interventional

Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid

NCT02274623
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Bone Neoplasms, Hypocalcemia, Hyperparathyroidism, Secondary
Interventions
CTAP101 Capsules
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Long Beach, California • Miami, Florida • Evergreen Park, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 29, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

Internal Radiation Therapy With or Without External-Beam Radiation Therapy in Treating Patients With Localized Prostate Cancer

NCT00714753
View directory record Official record
Conditions
Prostate Cancer
Interventions
brachytherapy, hypofractionated radiation therapy, image-guided radiation therapy, intensity-modulated radiation therapy
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 29, 2026, 5:49 PM EDT
Terminated Phase 2 Interventional

Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy

NCT00073970
View directory record Official record
Conditions
Prostate Cancer
Interventions
celecoxib
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Oct 29, 2026, 5:49 PM EDT
Not yet recruiting Not applicable Interventional

SURPASS: Stereotactic Ultra-hypofractionated Radiotherapy for Post-prostatectomy Patients: Adaptive Salvage SBRT

NCT07888283
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Adaptive stereotactic body radiotherapy (SBRT)
Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 29, 2026, 5:49 PM EDT
Terminated Phase 3 Interventional

GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer

NCT00089856
View directory record Official record
Conditions
Prostate Cancer
Interventions
Immunotherapy with allogeneic prostate vaccine, Chemotherapy (Taxotere and prednisone)
Biological · Drug
Lead sponsor
Cell Genesys
Industry
Eligibility
18 Years and older · Male only
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
83
States / cities
Alabaster, Alabama • Anchorage, Alaska • Glendale, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2008 · Synced Oct 29, 2026, 5:49 PM EDT
Recruiting Not applicable Interventional

Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial

NCT06496256
View directory record Official record
Conditions
Prostate Cancer
Interventions
Barrigel, Transrectal Ultrasound
Device
Lead sponsor
Palette Life Sciences, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
11
States / cities
Chandler, Arizona • Santa Barbara, California • Boca Raton, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 29, 2026, 5:49 PM EDT
Recruiting Not applicable Interventional

Comparing Acupuncture vs. Sham Acupuncture for the Management of Hot Flashes in Prostate Cancer Patients Receiving Hormone Therapy

NCT07594002
View directory record Official record
Conditions
Accupuncture, Prostate Cancer, Hormone Therapy, Hot Flashes
Interventions
Real Acupuncture, Sham Acupuncture
Device
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 29, 2026, 5:49 PM EDT